Advances in systemic therapies for metastatic castration-resistant prostate cancer - Abstract

The landscape of treatment for metastatic castration-resistant prostate cancer has rapidly evolved during the last 5 years alone.

In this review, standard therapies as well as recent advances in the systemic treatment for prostate cancer are explored. Pivotal trial data are summarized with emphasis on indications for various anti-androgen drugs, androgen-biosynthesis inhibitors, chemotherapy, immunotherapy and bone-targeted agents. The clinical, biochemical and radiographic outcomes for men with metastatic castration-resistant prostate cancer are improving with the establishment of several promising novel agents.

Written by:
Pant MK, Abughaban A, Aragon-Ching JB.   Are you the author?
Department of Medicine, Division of Hematology & Oncology, George Washington University Medical Center, 2150 Pennsylvania Avenue, NW Washington, DC 20037, USA.

Reference: Future Oncol. 2014 Nov;10(14):2213-26.
doi: 10.2217/fon.14.128


PubMed Abstract
PMID: 25471035

Beyond the Abstract

UroToday.com mCRPC Treatment Section

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe